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Myotubular myopathy (XLMTM, OMIM 310400) is a severe congenital muscular disease due to mutations in the
myotubularin gene (MTM1) and characterized by the presence of small myoﬁbers with frequent occurrence of
central nuclei. Myotubularin is a ubiquitously expressed phosphoinositide phosphatase with a muscle-speciﬁc
role in man and mouse that is poorly understood. No speciﬁc treatment exists to date for patients with myo-
tubular myopathy. We have constructed an adeno-associated virus (AAV) vector expressing myotubularin in
order to test its therapeutic potential in a XLMTM mouse model. We show that a single intramuscular injection
of this vector in symptomatic Mtm1-deﬁcient mice ameliorates the pathological phenotype in the targeted
muscle. Myotubularin replacement in mice largely corrects nuclei and mitochondria positioning in myoﬁbers
and leads to a strong increase in muscle volume and recovery of the contractile force. In addition, we used
this AAV vector to overexpress myotubularin in wild-type skeletal muscle and get insight into its localization
and function. We show that a substantial proportion of myotubularin associates with the sarcolemma and I
band, including triads. Myotubularin overexpression in muscle induces the accumulation of packed membrane
saccules and presence of vacuoles that contain markers of sarcolemma and T-tubules, suggesting that myo-
tubularin is involved in plasma membrane homeostasis of myoﬁbers. This study provides a proof-of-principle
that local delivery of an AAV vector expressing myotubularin can improve the motor capacities of XLMTM
muscle and represents a novel approach to study myotubularin function in skeletal muscle.
INTRODUCTION
Myotubular myopathy (XLMTM, OMIM 310400) is the
X-linked and most severe form of a group of muscular
disorders, named centronuclear myopathies (CNM), character-
ized by the presence of hypotrophic myoﬁbers with central
nuclei in skeletal muscle (1). Myotubular myopathy, which
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Advance Access published on April 22, 2008affects one newborn male in 50 000 is caused by mutations in
the ubiquitously expressed MTM1 gene that codes for a phos-
phoinositide phosphatase named myotubularin (2,3). Missense
mutations in DNM2 (dynamin 2) are found in most patients in
the autosomal dominant form (4,5), and recently, mutations in
amphiphysin 2/Bin1, a dynamin 2 interactor, have been found
in some patients with autosomal recessive CNM (6). XLMTM
patients are born with generalized hypotonia and muscle
weakness leading to respiratory difﬁculties, and most of
them either die during early postnatal life or survive with
intensive medical care (7,8). Skeletal muscle from XLMTM
patients contains hypotrophic ﬁbers with central nuclei sur-
rounded by a halo devoid of myoﬁbrils where mitochondria
and glycogen accumulate (9,10). Fiber size, but not the pro-
portion of myoﬁbers with central nuclei, shows a correlation
with clinical outcome (11). Mice deﬁcient for Mtm1 have
been generated and presented a clinical and pathological phe-
notype similar to the human condition (12). These mice are
born with normally differentiated muscle, but develop a pro-
gressive CNM starting at around 3–4 weeks of age, with
amyotrophy and structural myoﬁber disorganization, leading
to death at 6–12 weeks. As muscle differentiation and matu-
ration appear normal in these mice, we have proposed that
defects in maintenance of muscle cell architecture are respon-
sible for the internalization of nuclei and other organelles. The
same phenotype is observed when the Mtm1 gene is inacti-
vated only in skeletal muscle, indicating that myotubularin
exerts a muscle autonomous function (12).
MTM1 belongs to a large disease-associated gene
family with 14 members in humans, including MTMR2 and
MTMR13, which are mutated in demyelinating Charcot-Marie-
Tooth type 4B1 and 4B2 neuropathies, respectively (13–16).
Myotubularins are subdivided into active and inactive
phosphatases (16). Active family members dephosphorylate
speciﬁc phosphoinositides, PtdIns3P and PtdIns(3,5)P2,
which are lipid second messengers mainly associated with
endosomes, and appear involved in the regulation of endocytic
pathways (17). Most myotubularins are cytoplasmic proteins
that also associate with peripheral and/or internal membranes,
as investigated in overexpression systems (18–22). In particu-
lar, the MTM1 protein appears cytoplasmic in various cell
lines and has been found associated with endosomes (20,23).
Its overexpression induces the formation of ﬁlopodia-like pro-
jections and affects protein trafﬁcking from late endosome to
lysosome (20,24). No data have been reported up to date on
the subcellular localization and speciﬁc function of myotubu-
larin in muscle ﬁbers.
Recombinant adeno-associated viruses (rAAV) represent a
powerful tool to express transgenes in vivo, and several sero-
types transduce with high efﬁciency skeletal muscle (25). In
order to evaluate the feasibility for viral-mediated Mtm1
gene transfer as a therapeutic approach, we have injected an
rAAV2/1 vector containing the Mtm1 cDNA into skeletal
muscle of XLMTM mice. Our results demonstrate that myo-
tubularin replacement in a mouse model of the disease is
sufﬁcient to correct the pathology and strength of affected
muscles and thus opens novel perspectives for therapy in
patients with myotubular myopathy. Furthermore, AAV-
mediated expression of myotubularin in skeletal muscle can
also be used for functional analysis. Its overexpression in
wild-type (WT) muscle generates a striking proliferation of
membrane structures that contain myotubularin and the pre-
sence of vacuoles that are labeled by markers of sarcolemma
and T-tubules. Vacuoles present in Mtm1-deﬁcient muscle
appear also derived from sarcolemma and T-tubules. These
results suggest that myotubularin regulates plasma membrane
homeostasis and/or remodeling in skeletal muscle.
RESULTS
Skeletal muscle pathology of Mtm1-deﬁcient mice
before AAV-mediated gene transfer
Constitutive and muscle-speciﬁc Mtm1-deﬁcient mice develop
a progressive and generalized myopathy starting at 3–4 weeks
of age and leading to early death (12). We have assessed the
efﬁcacy of viral-mediated Mtm1 transduction in the muscle-
speciﬁc mutant line (Mtm1/HSA ¼ mKO) to avoid an
immunological reaction against the transgene. The tibialis
anterior (TA) muscle of 4 week-old muscle-speciﬁc knockout
(mKO) mice was selected for rAAV vector injection, a widely
used muscle for gene therapy experiments, because weakness
was already present in hindlimbs at this age (animals were in
clinical phase II, see 12). At 4 weeks of age, the weight of the
TA muscle is lower by 40% in muscle-speciﬁc mutant
(mKO) compared with WT mice (Fig. 1A) and the mean
area of TA muscle ﬁbers is signiﬁcantly smaller (428+
170 mm
2 in mKO versus 639+217 mm
2 in WT animals,
P , 0.001, Fig. 1B), with the presence of many very small
myoﬁbers (23% of them being ,230 mm
2) that are not
present in WT muscle at this age (Fig. 1B and C). Within
muscle ﬁbers, mitochondria appears already mislocalized at
this stage of the disease, as assessed by oxidative staining,
whereas most nuclei are still at their normal position
beneath the sarcolemma (Fig. 1C).
Intramuscular injection of a rAAV2/1-Mtm1 vector
ameliorates the histological phenotype of
myotubularin-deﬁcient muscle
To explore the efﬁcacy of Mtm1 cDNA replacement in block-
ing the progression of XLMTM muscle pathology, we injected
9   10
10 vg of rAAV2/1-CMV-Mtm1 into the TA of 4
week-old Mtm1/HSA male mice. The contralateral muscle
was injected with phosphate-buffered saline (PBS) as an
internal control. Since the myopathy progresses rapidly and
mice die early during postnatal life (at mean age of 56
days), the effect of AAV-mediated myotubularin expression
was analyzed 4 weeks after injection. Immunoﬂuorescence
analysis of AAV-transduced mKO muscle cross-sections
using novel polyclonal antibodies (discussed later) demon-
strated that overexpressed myotubularin is present in most
myoﬁbers (Fig. 2A) and located throughout the cytoplasm
with a clear reinforcement in the sarcolemmal region.
Figure 2B shows that myotubularin re-expression in
Mtm1-deﬁcient muscle leads to a doubling in muscle mass
(26.5+3.1 mg in transduced compared with 12.3+1.7 mg
in mKO TA) that correlates with an increase in the volume
of myoﬁbers. Indeed, the mean area of AAV-treated mutant
muscle ﬁbers is three times larger than that of mKO mice
Human Molecular Genetics, 2008, Vol. 17, No. 14 2133(970,76+338,24 mm
2 in mKO-AAV versus 314.05+
129.34 mm
2 in mKO-PBS), and corresponds to 50% of the
mean area of WT muscle ﬁbers (1784.91+644.3 mm
2,
Fig. 2C). Analysis of the distribution of myoﬁber areas
shows a clear shift of the curve to the right, indicating an
overall increase of the volume of treated muscle ﬁbers
(Fig. 2D). The percentage of myoﬁbers with an area
,533 mm
2 shifts from 93% in the mKO population to only
18% after AAV treatment. In addition to ﬁber hypotrophy,
centronucleation represents another hallmark of XLMTM
pathology. We thus counted the number of ﬁbers with internal
nuclei in treated versus untreated TA muscle and observed a
strong reduction in the percentage of ﬁbers with internalized
nuclei 4 weeks after viral injection (10.3% in treated compared
with 26.5% in untreated mutant muscle, Fig. 3A). Finally,
murine myotubularin-deﬁcient muscle ﬁbers are also charac-
terized by a progressive disorganization of the distribution of
organelles. Thus, we evaluated the location of mitochondria
and endoplasmic reticulum by nicotimanide adenine dinucleo-
tide tetrazolium reductase (NADH-TR) staining in mKO myo-
ﬁbers after rAAV2/1-CMV-Mtm1 transfer. Figure 3B shows
that the morphology of mutant muscle ﬁbers is restored by
AAV treatment, as well as the internal architecture, since
the distribution of the oxidative enzyme activity is similar to
WT muscle. Similar results were obtained when sections
were stained for succinate dehydrogenase activity, which
reﬂects mitochondrial function (data not shown). Vacuoles
that are observed in a small proportion of Mtm1-deﬁcient myo-
ﬁbers at 8 weeks of age (but not at 4 weeks) (12) are decreased
in number in transduced ﬁbers (data not shown). Occasional
small foci of inﬂammatory inﬁltrates were observed in AAV-
transduced mKO muscles, often nearby myoﬁbers expressing
high levels of myotubularin (Fig. 3C). Altogether, our
results demonstrate that a single intramuscular injection of a
rAAV vector carrying a Mtm1 cDNA is sufﬁcient to amelio-
rate the pathology of an already affected XLMTM muscle.
Myotubularin replacement restores the contractile
force of Mtm1 mutant muscle
We tested whether AAV-mediated myotubularin replacement
could be beneﬁcial at the functional level because muscle
weakness is the constant and life threatening sign of the
disease. Brieﬂy, 2.5 and 9   10
10 vg of rAAV2/
1-CMV-Mtm1 were injected into the right extensor digitorum
longus (EDL) and TA muscles of 4 week-old mKO mice,
respectively. Four weeks later, mice were anesthetized and
muscles excised for in vitro measurement of the force. Like
TA, the EDL showed a clear increase in muscle mass
(5.7+0.5 mg in mKO-AAV compared with 3.6+0.1 mg in
mKO-PBS EDL muscle, n ¼ 6 for each group, P , 0.0006),
indicating that AAV transduction and myotubularin
expression were also efﬁcient in this muscle, see
Figure 4A. We measured the speciﬁc isometric force of
untreated EDL and TA muscles of 8 week-old myotubularin-
deﬁcient mice and found that strength was lower by 80%
in both muscles compared with WT (Fig. 4B). No difference
in the resistance of mKO muscles to mechanical stretch was
Figure 1. Pathology of tibialis anterior (TA) muscle of 4 week-old Mtm1 mutant mice. (A) Weight of wild-type (WT) and Mtm1/HSA [mKO (muscle-speciﬁc
knockout)] TA muscles (n ¼ 4 and 8 muscles for WT and mKO, respectively). Note the important reduction of muscle mass in mutant mice ( P , 0.001).
(B) Area of TA myoﬁbers. The curve represents the percentage of muscle ﬁbers per area group (myoﬁber areas were divided into 20 groups, n ¼ 496 and
771 for WT and mKO ﬁbers, respectively, P , 0.001). The curve is shifted to the left in mKO animals indicating a general decrease of myoﬁber areas.
(C) Hematoxylin and eosin (left panels, HE, magniﬁcation  400) and nicotimanide adenine dinucleotide tetrazolium reductase (NADH-TR) (right panels, mag-
niﬁcation  200) staining of TA cross-sections from WT (top) and mKO (bottom) mice at 4 weeks of age. Note the presence of very small myoﬁbers (arrow) and
nuclei beneath the sarcolemma. Mitochondrial oxidative staining is often distributed as a ring at the periphery of the muscle ﬁbers.
2134 Human Molecular Genetics, 2008, Vol. 17, No. 14observed, as tetanic force values remained similar after a
series of ﬁve eccentric contractions (data not shown). Impor-
tantly, viral-mediated myotubularin expression led to the cor-
rection of EDL and TA muscle-speciﬁc forces in mutant mice,
reaching a level similar to WT animals (Fig. 4B). The strength
of EDL muscles 4 weeks after AAV injection represents
75% that of normal muscles and the tension of treated TA
muscles is not signiﬁcantly different than of WT muscles.
This functional recovery could even be visualized at the clini-
cal level, as mice were able to climb on objects more efﬁ-
ciently than untreated mice and could grasp on objects with
their AAV-treated hindlimbs (Supplementary Material,
Video).
Localization of myotubularin in skeletal muscle
The speciﬁc function of myotubularin and its subcellular
localization in skeletal muscle are presently unknown.
Previous attempts to localize the endogenous protein by
immunohistological methods have failed (unpublished data).
We raised a novel polyclonal antibody against the C-terminal
part of mouse myotubularin and show that it detects the
endogenous protein by direct western blotting (Fig. 5A),
while all previously generated monoclonal and polyclonal
antibodies required an additional immunoprecipitation step
(20). This antibody does not cross-react with either mouse
MTMR1 or MTMR2 (the closest paralogues of MTM1), as
assessed by transfection of expression plasmids in COS cells
(data not shown). Myotubularin is ubiquitously expressed in
mouse tissues, being more abundant in striated muscles than
in sciatic nerve and brain, and increases during the ﬁrst post-
natal week in skeletal muscle (Supplementary Material,
Fig. S1). The sensitivity of this novel antibody in skeletal
muscle is rather low by immunohistochemistry but was sufﬁ-
cient to detect endogenous myotubularin on semithin sections
(Fig. 5B). Speciﬁc myotubularin labeling was found in a
region of the I-band and appeared as two distinct bands ﬂank-
ing markers of the Z-line (a-actinin). These bands colocalize
with markers of the triad (ryanodine receptor and triadin).
A third band in the region of the M-line, is detectable in
Mtm1 KO mice and represents a cross-reacting, but unrelated
protein. We failed, however, to detect endogenous myotubu-
larin at the ultrastructural level. In order to increase sensitivity,
we further analyzed myotubularin localization overexpressed
in the TA of WT mice, 4 weeks after injection of 9   10
10
vg of the rAAV2/1-CMV-Mtm1 vector. Speciﬁc staining for
myotubularin was found at the sarcolemma and in a region
of the I-band, where staining also appears predominantly
around the Z-line as a double row (Fig. 5B). To further inves-
tigate the precise location within the I-band, we performed
immunoelectron microscopy on muscle sections and found
that myotubularin associates with the triad, a specialized
Figure 2. Myotubularin replacement leads to increased muscle volume. (A) Expression of myotubularin in muscle-speciﬁc knockout (mKO) muscle after
rAAV2/1 transduction. phosphate-buffered saline (PBS) and adeno-associated virus (AAV)-treated mutant tibialis anterior (TA) cross-sections (mKO-PBS
and mKO-AAV) were immuno-labeled with a rabbit polyclonal antibody against myotubularin. The antibody labels aspeciﬁcally nuclei in mutant
muscle, whereas it detects myotubularin throughout the ﬁber with reinforcement in the sarcolemmal region 4 weeks after rAAV2/1-CMV-Mtm1 vector trans-
fer (magniﬁcation  400). (B) Weight of mutant TA muscle after myotubularin re-expression. The weight of isolated TA was measured 4 weeks after viral
transduction (mKO-AAV) and compared with PBS-injected wild-type (WT) and mKO muscles (n ¼ 6 for WT-PBS and mKO-AAV, n ¼ 7 for mKO-PBS).
The weight is lower by about four times in mutant animals (mKO-PBS,  P ¼ 2   10
26), but signiﬁcantly increased after rAAV (recombinant AAV) transfer
( P ¼ 2   10
25). (C) Evaluation of mean myoﬁber area 4 weeks after intramuscular injection of rAAV2/1-CMV-Mtm1 vector. The size of Mtm1-deﬁcient
TA muscle ﬁbers is smaller than WT animals (n ¼ 473 from ﬁve mice and n ¼ 1555 from four mice for WT-PBS and mKO-PBS, respectively,  P , 0.001).
Viral transduction leads to a strong increase in myoﬁber area (n ¼ 636 from four mice for mKO-AAV,  P , 0,001). (D) Distribution of muscle ﬁbers from
TA according to their size. The areas were subdivided into 20 subgroups ranging from the smallest to the biggest area, the interval between each subgroup
corresponds to 82 mm
2. The curve represents the percentage of ﬁbers that belongs to each of the subgroups according to genotype and treatment. Note the
strong reduction of very small ﬁbers in mKO-AAV muscle.
Human Molecular Genetics, 2008, Vol. 17, No. 14 2135structure where the excitation–contraction coupling takes
place (Fig. 5C). Because of the size of the epitope–anti-
body–gold particle complex, it is not possible to distinguish
between a location at the junctional sarcoplasmic reticulum
and at the T-tubule within the triad. Overexpressed myotubu-
larin, like the endogenous one, is present as a doublet in skel-
etal muscle by western blot (Fig. 5D), indicating that these
isoforms result from post-translational modiﬁcation of the
protein rather than alternative splicing of the Mtm1 gene.
We also compared the distribution of endogenous and over-
expressed myotubularin in skeletal muscle by subcellular
fractionation. We found that, in both conditions, myotubularin
is distributed in the cytosolic S3 fraction, containing
glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
and in the membrane P3 fraction, containing caveolin 3
(which is associated with sarcolemmal caveolae) (Fig. 5D).
These results suggest that overexpressed myotubularin has a
similar distribution than the endogenous protein within
muscle ﬁbers and validate the use of AAV-mediated over-
expression for functional studies.
Overexpressed myotubularin induces a plasma
membrane pathology in skeletal muscle
In order to get insights into myotubularin function in skeletal
muscle, we analyzed the effect of its overexpression. We
Figure 3. Correction of XLMTM (X-linked myotubular myopathy) pathology by viral-mediated myotubularin treatment. (A) Percentage of muscle ﬁbers with
internalized nuclei after adeno-associated virus (AAV)-mediated myotubularin expression. Myonuclei were considered as internalized if detached from the
sarcolemma. The number of ﬁbers with internal nuclei is increased in mutant tibialis anterior (TA) muscle (n ¼ 311 for WT-PBS (wild-type-phosphate-buffered
saline) and n ¼ 1181for mKO(muscle-speciﬁc knockout)-PBS,  P , 0,001) and signiﬁcantly reduced 4 weeks after viral injection(n ¼ 487 for mKO-AAV,  P ,
0,001). (B) Histological aspect of myotubularin-deﬁcient skeletal muscle 4 weeks after rAAV2/1-CMV-Mtm1 transfer. Hematoxylin and eosin, HE (upper panels,
magniﬁcation  400) and nicotimanide adenine dinucleotide tetrazolium reductase (NADH-TR) (lower panels,  630) stainings of TA cross-sections from WT
(left),mutant(middle)andAAV-treated (right)mice.Notetherecoveryofoxidativereactivitypatterninmyotubularin-expressingmKOmuscle.(C)Immunostain-
ingofmKOmusclecross-sections4weeksafterrAAV-Mtm1injectionwithmyotubularinantibodies(left)andHoechst(middle).RightpanelisthemergeofMTM1
labeling and Hoechst. Right panel shows an inﬂammatory inﬁltrate in a region where myotubularin is highly overexpressed ( 400).
2136 Human Molecular Genetics, 2008, Vol. 17, No. 14injected a higher dose of rAAV2/1-CMV-Mtm1 vector (12  
10
10 vg) into the TA of 4 week-old WT animals. Mice were
euthanized for analysis 6–8 weeks later (compared with 4
weeks in the former experiments). In these conditions, we
observed a higher frequency of pathologic features in trans-
duced ﬁbers than with the gene therapy protocol. These patho-
logical effects are speciﬁc for myotubularin overexpression as
they were not observed when other rAAV2/1 vectors, contain-
ing either murine secreted alkaline phosphatase or green-
ﬂuorescence protein cDNAs under the same CMV (cytomega-
lovirus) promoter, were injected into skeletal muscle (data not
shown). Figure 6A shows that myotubularin overexpression
leads to the presence of vacuoles and needle-like structures
in myoﬁbers, as observed in semithin sections. Vacuoles
were found in 35% of muscle ﬁbers and were caveolin-3,
dystrophin and dihydropyridine receptor (DHPR)-positive
but laminin 2-negative, indicating that they originate from
the sarcolemma and/or T-tubules (Supplementary Material,
Fig. S2). One can note that a few large vacuoles that are
observed during the evolution of pathology in the Mtm1 KO
mouse (12) are similarly labeled by these membrane
markers (Supplementary Material, Fig. S3). In AAV-
transduced ﬁbers, the large vacuoles are either empty or
contain internal membranes (Fig. 6A and discussed later),
suggesting in the latter case that they originate from the
degeneration of the needle-like structures. Ultrastructural
analysis of TA muscle overexpressing myotubularin revealed
that the needle-like structures are highly organized membrane
assemblies, which were often located in the subsarcolemmal
region of the ﬁber (Fig. 6B). These were sometimes associated
with honeycomb structures, typical of abnormal proliferation
of the T-tubule system (26). Small autophagic vacuoles con-
taining undigested material were also occasionally observed
(Fig. 6B). We found by immunoﬂuorescence and immunoelec-
tron microscopy that myotubularin strikingly accumulates on
these membrane assemblies and may thus contribute to their
formation (Fig. 6C and Supplementary Material, Fig. S4).
To better understand the organization of these myotubularin-
associated membranes, we performed electron-tomography
experiments to reconstitute the three-dimensional (3D) archi-
tecture of these assemblies. Figure 6D shows that they are
not tubules, as initially suggested by the electron microscopy
features, but instead are formed by membrane saccules,
often piled-up in an almost parallel, slightly twisted, arrange-
ment. Upon interaction, the saccules form an electron dense
interface with a constant width of 14–16 nm whereas the out-
ermost saccule is closed by a thinner membrane 7 nm wide.
These measurements indicate that the electron dense interface
is composed of two lipid bilayers held together at a constant
distance probably through an interaction with an abundant
adhesion molecule. Although they were often in close
contact with the sarcolemma, we could not detect a direct
continuity between the membrane of these saccules and the
plasma membrane or other membranous compartments.
However, we noticed the presence of vesicles that appear
derived from the plasma membrane, which are loosely
attached to the membranous proliferations (Fig. 6D). The mor-
phological abnormalities found upon myotubularin overex-
pression had no detectable effect on the contractile force of
isolated muscles (data not shown).
DISCUSSION
X-linked myotubular myopathy is, in most cases, a very severe
and life threatening congenital disease that has no speciﬁc or
curative treatment. In the present study, we have injected a
recombinant rAAV2/1 vector expressing the Mtm1 cDNA into
the skeletal muscle of symptomatic XLMTM mice to test the
efﬁciency of this therapeutic approach. Several successful gene
therapy studies using AAV vectors in mouse models of human
muscular diseases have been reported to date and, more recently,
Figure 4. Recovery of the contractile force in Mtm1-deﬁcient skeletal muscle. (A) Extensor digitorum longus (EDL) and tibialis anterior (TA) muscle cross-
sections 4 weeks after viral injection. The photographs illustrate the important increase in the volume of both mutant muscles. The bars represent 1 mm.
(B) The histogram represents the isometric contractile force (mean+SD) of isolated EDL and TA normalized by muscle length. Strength was also measured
4 weeks after injection. Results show a signiﬁcant decrease in muscle force between wild-type and mKO animals at 8 weeks of age ( P , 0.001), whereas an
important recovery of strength is observed after myotubularin treatment (force is about ﬁve times higher in treated versus untreated muscles, P-value between
mKO-PBS (muscle-speciﬁc knockout-phosphate-buffered saline) and mKO-AAV (muscle-speciﬁc knockout-adeno-associated virus) is P ¼ 0.0006 for both
muscles).
Human Molecular Genetics, 2008, Vol. 17, No. 14 2137a protocol combining a brief course of immunosupression to
rAAV delivery in a dog model of Duchenne muscular dystrophy
has shown a sustained expression of the transgene product in
muscles (27–31). We show that the XLMTM phenotype
can be corrected in murine muscle by virally mediated Mtm1
replacement. A vector expressing myotubularin under the
CMV promoter was injected into the TA of muscle-speciﬁc
mutant mice (mKO) at 4 weeks of age, when pathology and
Figure 5. Subcellular localization of myotubularin in skeletal muscle. (A) Detection of endogenous myotubularin by western blot. Left panel shows the presence
of myotubularin in wild-type (WT) but not KO skeletal muscle and heart. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) immunoreactivity was used as
an internal control. Right panel illustrates the level of expression of myotubularin 6 weeks after adeno-associated virus (AAV) injection; 75 and 7.5 mg of pro-
teins were loaded for phosphate-buffered saline (PBS) (LTA) and AAV (RTA)-injected WT muscles, respectively. A lower exposure of myotubularin band in
RTA (RTA ) is shown to illustrate the doublet. (B) Localization of endogenous myotubularin in skeletal muscle. Semithin cryosections (0.5 mm) of WT muscle
were stained for MTM1 (myotubularin), a-actinin (Z-lines), ryanodine receptor (RYR) and triadin (both in triads). Occasional a-actinin-positive Z-lines appear
yellow when oblique orientation of the sarcomeres in sections superimpose the Z-lines with the adjacent triadic regions. The bar represents 5 mm. (C) Local-
ization of overexpressed myotubularin in skeletal muscle. Semithin Mtm1-deﬁcient (upper panels) and WT-AAV (middle and lower panels) muscle cryosections
were stained for MTM1, SERCA1 (sarco-endoplasmic reticulum calcium ATPase 1) and a-actinin. Myotubularin antibody binds aspeciﬁcally to a region
between I-bands in WT and KO myoﬁbers, which probably corresponds to the M-band. Note myotubularin location at the sarcolemma (arrowheads) and
around the Z-line (arrows) in WT-AAV muscle. The Z-line and I-band (endoplasmic reticulum) were labeled with antibodies against a-actinin and
SERCA1, respectively. The bar represents 5 mm. (D) Subcellular localization of overexpressed myotubularin by immunoelectron microscopy. Triads
(arrows) are labeled by r1947-coupled gold particles. Note the position of mitochondria (m, bar represents 200 nm). (E) Subcellular fractionation of skeletal
muscle overexpressing myotubularin (upper panel) and wild-type muscle (lower). Proteins from total homogenate (HT), S1 (supernatant at 1000g), S2
(10 000g), S3 (100 000g) and the corresponding pellet fractions (P1, P2 and P3) were analyzed by immunoblotting. Myotubularin is distributed along all frac-
tions. We used myosin heavy chain (MHC) and GAPDH as internal controls for cytosolic fractions. GRP78/BiP and caveolin 3 (CAV3) immunoreactivities are
indicative of membrane fractions. Antibody r1947 was used in all illustrated experiments.
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phase II, see 12). At this age, mKO myoﬁbers are hypotrophic
and contain mislocalized mitochondria, whereas most nuclei
are still at their normal position beneath the sarcolemma. This
suggests that, in mice, myotubularin might be primarily involved
in myoﬁber growth and internal organelle positioning.
Four weeks after rAAV2/1-CMV-Mtm1 injection, XLMTM
muscle histology was strikingly corrected, in particular, there
was an overall increase in muscle and myoﬁber volume. Trans-
duced mutant ﬁbers showed a normal architecture with most
nuclei at the periphery and an even distribution of mitochondrial
NADH-TR staining, compared with the presence of internalized
nuclei and mislocalized mitochondria inuntreated muscle at this
age. In 8 week-old mutant TA, many nuclei were detached from
the sarcolemma and internalizedbut not necessarilyatthe centre
ofmyoﬁbers.Centralizationofnucleiappearsthusasaprogress-
ive event and varies between muscles, as previously described
(12). Myotubularin replacement in mutant muscle also led to
the recovery of contractile force deﬁcits, which could even be
visualized at the clinical level. This functional beneﬁt was
already observed 2 weeks post-injection (data not shown).
Some signs of inﬂammation were observed in mKO muscle 4
weeks after rAAV2/1-CMV-Mtm1 injection that can be attribu-
ted to high expression of the transgene, without apparent reper-
cussion on motor activity. The long-term effect of this vector
couldnotbeassessedasXLMTMmicedieearlyduringpostnatal
life (12). It will thus be important to test whether myotubularin
replacement in most skeletal musculature by systemic delivery
of rAAV vectors (32, 33) prolongs survival of Mtm1 mutant
mice.Recently,aspontaneousdogmodelofmyotubularmyopa-
thy has been identiﬁed and may represent a useful model
to further extend studies of gene therapy in the future if a
colony can be established (Shelton G.D., www.wms2007.com/
download/Full%20programme.pdf).
Apparently low levels of myotubularin expression in skel-
etal muscle had previously precluded determination of myo-
tubularin’s subcellular localization in this tissue. However,
development of the new r1947 antibody, together with the
use of AAV-mediated transduction to overexpress myo-
tubularin, permitted us to demonstrate that it preferentially
localizes to the triadic region, and perhaps also to the sarco-
lemma. Immunostaining of normal quadriceps semithin
sections revealed a sarcomeric pattern of three bands; two
speciﬁc ones ﬂanking the Z-lines and co-localizing with
ryanodine receptors and triadin, and a third non-speciﬁc
band, seen in myotubularin-deﬁcient muscle, at the M-line.
Confocal microscopic examination of AAV transduced
muscle overexpressing myotubularin revealed considerably
stronger signal at the triads and speciﬁc localization at the sar-
colemma as well. This sarcolemmal staining demonstrates that
myotubularin is certainly capable of membrane association at
this site; although it is presently unclear whether biologically
signiﬁcant amounts of endogenous protein are present there.
Given this propensity to associate with the plasma membrane,
we believe that triadic myotubularin may bind at T-tubules
which are the plasma membrane invaginations that, together
with terminal cisternae of sarcoplasmic reticulum, form the
triads where excitation–contraction coupling occurs (34).
Subcellular fractionation studies provided further conﬁrmation
that the localization of overexpressed myotubularin in muscle
likely corresponds to that of the endogenous protein as they
revealed a similar pattern of distribution. These results
contrast with previous studies showing that endogenous
myotubularin is mainly cytoplasmic in C2C12 myotubes
(20) and suggest that it associates with sarcolemma and
triads only upon myoﬁber maturation. The inability to
Figure 6. Effect of overexpression of myotubularin in skeletal muscle. (A)
Presence of needle-like structures (left panel, arrows) and vacuoles (right
panel) in wild-type muscle overexpressing myotubularin. Semithin cross-
sections of tibialis anterior were stained with toluidine blue ( 630, left and
 1000, right). (B) Electron micrographs illustrate the nature of
myotubularin-induced needle-like structures (left and middle panels). They
resemble myelin-like structures and are occasionally associated with honey
combs-like structures (arrow, middle panel). Note that the basal lamina
(arrowhead) is not included. Vacuoles often contain degenerative membrane
aggregates (arrow, right panel). Occasional authophagic vacuoles are also
present (arrowhead). Bars represent 2 mm in the left and right panels and
400 nm in the middle panel. (C) Immunogold detection with an anti-
myotubularin antibody shows labeling of the sarcolemma (arrowheads) and
an intense signal on the membrane aggregates. Bars indicate 200 nm. (D)
Left panel: central section of an electron tomogram from a cellular region con-
taining such a membrane assembly. Membrane sheets clearly appear as being
composed of two bilayers. Vesicular structures can be found attached to the
membrane sheets (arrow). Central panel: section through the membrane
assembly normal to the section plane as indicated by the dotted line in the
left panel. This cross-section demonstrates that the lipid assemblies are ﬂat
layers and not tubular structures. Right panel: surface representation of the
lipid layers which evidences the twisted nature of the close to parallel lipid
assemblies. The bar represents 200 nm in the left and central panels and
125 nm in the right panel.
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well-differentiated myotubes from XLMTM patients suggests
indeed that myotubularin plays a speciﬁc and non-redundant
function in mature myoﬁbers (35).
Our results indicate that when highly overexpressed in
skeletal muscle, myotubularin alters membrane homeostasis
leading to the formation of packed membrane assemblies
close to the sarcolemma and of vacuoles that are positive for
dystrophin, caveolin-3 and DHPRa, markers of plasma mem-
brane and T-tubules. Electron tomography experiments
showed that these structures are piled membrane structures,
which form large and ﬂat saccules. We propose that
myotubularin-induced membrane assemblies originate either
from the aggregation and fusion of endocytic vesicles or
from plasma membrane remodeling. Several studies have
shown that caveolin-3 containing caveolae, which are
plasma membrane invaginations contribute to T-tubule bio-
genesis by the formation of reticular T-tubule elements in
the absence of caveolae ﬁssion (36,37). Thus, it may be possi-
ble that excessive caveolae formation upon myotubularin
overexpression contributes to the formation of these mem-
brane structures. Abnormal oblique and longitudinal
T-tubules have been observed in muscle biopsies from some
XLMTM patients (38). Myotubularin could thus be implicated
in remodeling longitudinal T-tubules to become transverse and
in the maintenance of triads. Defects in the organization of
these membrane structures would result in impairment of exci-
tation–contraction coupling, leading to muscle weakness and
atrophy (39). Recently, mutations in the amphyphisin 2/Bin1
gene in patients with an autosomal recessive form of CNM
were shown to alter its membrane tubulation properties and
interaction with dynamin 2 (6). Amphyphisin 2, which is
located on T-tubules in muscle ﬁbers, is involved in
T-tubule biogenesis and appears essential for the organization
of triads in Drosophila (40,41). Like in muscle biopsies from
CNM patients, and in particular from patients carrying amphy-
phisin 2/Bin1 mutations (6,42), Mtm1-deﬁcient murine muscle
contains vacuoles positive for sarcolemma and T-tubule
markers, such as caveolin 3 and DHPR-a. Similarly, biopsies
from patients with hypokalaemic periodic paralysis, which is
due to mutations in CaV1.1 (DHPR-a) or NaV1.4 (skeletal
muscle voltage-gated sodium channel) leading to alterations
in sarcolemmal depolarization, also contain similar vacuoles
(42). Thus, these results suggest that defects in the exci-
tation–contraction-coupling machinery may indeed be
involved in XLMTM pathogenesis and that a functional link
between myotubularin and amphyphisin 2 exists in skeletal
muscle. An implication of membrane homeostasis and remo-
deling as an important pathomechanism in XLMTM and
CNM is also supported by the striking involvement of other
myotubularins (MTMR2 and MTMR13) and dynamin 2 in
demyelinating neuropathies with abnormal myelin folding
(13–15,43), and by the implication of the dynamin 2 gene
in both autosomal dominant CNM and dominant intermediate
Charcot-Marie-Tooth neuropathy type 2 (4,5,43,44).
Alternatively, albeit non-exclusively, the muscle pathology
in XLMTM, and especially the striking muscle ﬁber hypotro-
phy might be related to the proposed involvement of myotubu-
larin in the regulation of early and late endosomal function
(23,24). The hypotrophy observed in Mtm1-deﬁcient muscle
ﬁbers might result from defects in endocytosis of receptors
involved in signaling pathways that are important for muscle
growth, such as the insulin growth factor receptor 1, IGFR1
(45,46). The abnormal membrane structures observed upon
AAV-mediated myotubularin overexpression in muscle could
result from an imbalance between membrane internalization
and recycling during endocytosis.
In conclusion, we provide evidence that myotubularin is
partly a membrane-associated phosphatase in skeletal muscle
ﬁbers that plays an important role in plasma membrane
homeostasis. In addition, our results indicate that gene
therapy by local Mtm1 transfer in skeletal muscle improves
the strength of the targeted muscle in a mouse model of
myotubular myopathy and might open novel strategies for
treating this disorder.
MATERIALS AND METHODS
Generation of rAAV
Mouse Mtm1 cDNA (AF073996, NCBI) was cloned by PCR
with speciﬁc oligonucleotides containing restriction enzyme
sites in the AAV expression plasmid pGG2-CMV-MCS
plasmid in order to obtain the plasmid pGG2-Mtm1WT,
where the Mtm1 gene is under the transcriptional control of
IE CMV promoter. Adenovirus-free pseudotyped AAV2/1
preparations were generated by tri-transfection of HEK293
cells with the plasmids pAAV2-CMV-Mtm1, pXX6 encoding
adenovirus helper functions (47) and pLT-RCO2, which con-
tains the AAV2 rep and AAV1 cap genes (a kind gift of
R. Mulligan, Harvard University). Recombinants vectors
were puriﬁed by double cesium chloride ultracentrifugation
gradients from cell lysates, followed by dialysis against
sterile PBS. Physical particles were quantiﬁed by real time
PCR and vector titers are expressed as viral genomes per ml
(vg/ml). The rAAV2/1-Mtm1 titer used in this study corre-
sponds to 6.2   10
12 viral genomes per ml (vg/ml).
Intramuscular delivery of AAV vectors
Four week-old male WT and Mtm1/HSA mice were anesthe-
tized by intraperitoneal injection of 5 ml/body gram of keta-
mine (20 mg/ml, Virbac) and xylazine (0.4%, Rompun,
Bayer). TA muscles were injected with 15 ml of either
rAAV2/1-Mtm1 or sterile PBS solution. TA muscles were dis-
sected under anesthesia 4–8 weeks after injection and frozen
in nitrogen-cooled isopentane and liquid nitrogen for histo-
logical and immunoblot assays, respectively. Care and
manipulation of mice were performed in accordance with
national and European legislations on animal experimentation,
and approved by the institutional ethical committee.
Antibodies
A C-terminal peptide (TSSSSQMVPHVQTHF) corresponding
to amino acid residues 589–603 from mouse myotubularin
was coupled with ovalbumin and injected into rabbits.
Polyclonal antibodies were puriﬁed using the same peptide
bound to Sulfolink Coupling Gel (Pierce) according to
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storage. This antibody, r1947, was used for immunoblots
and immunohistochemistry. Other antibodies used in this
study are: monoclonal antibodies against glyceraldehyde-3-
phosphate dehydrogenase (MAB374, Chemicon), caveolin 3
(610420, BD Transduction Laboratories), pan-myosin
(MF20, Developmental Studies Hybridoma Bank) and rabbit
polyclonal anti-GRP78 (PA1-014, Afﬁnity BioReagents) for
immunoblot analysis, and monoclonal anti-ryanodine receptor
(clone 34C, Sigma), anti-triadin (clone IIG12, Sigma), anti-
SERCA1 (sarco-endoplasmic reticulum calcium ATPase 1)
(MA3-911, Afﬁnity BioReagents) and anti-a-actinin (EA-53,
Sigma) for immunohistochemistry.
Immunoblot analysis
Western blotting. Muscles were homogenized in 50 mM Tris,
10% glycerol, 1 mM EDTA, 50 mM KCl, 10 mM beta-
glycerophosphate, 10 mM NaF, 1 mM Na3VO4, 0.1% SDS,
2% Triton X and protease inhibitors (PIC, Roche Diagnostics)
using a Polytron homogenizer, kept in ice for 10 min, and cen-
trifuged at 2000 rpm (5417R, Eppendorf) for 10 min. The
supernatant was recovered and proteins were quantiﬁed with
the Biorad Protein Assay detection kit. Proteins were trans-
ferred to nitrocellulose membranes.
Subcellular fractionation. TA muscles were homogenized in
10 mM NaHCO3, 0.2 mM CaCl2, PIC, and mixed in an equal
volume of 500 mM sucrose, 300 mM KCl, 4 mM MgCl2,
60 mM histidine, pH 7.4. The suspension (total homogenate)
was centrifuged at 1000 g for 20 min. The pellet (P1) was
resuspended in PBS, 2% Triton X and PIC and the supernatant
(S1) was further centrifuged at 10 000 g for 20 min. The
pellet (P2) was also resuspended in PBS, 2% Triton X and
PIC, and the supernatant (S2) was centrifuged at 100 000g
for 30 min. The supernatant (S3) was recovered as the
cytosolic fraction and the pellet (P3) was washed in a solution
containing 250 mM sucrose, 600 mM KCl, 3 mM MgCl2,
30 mM histidine, pH 7.4, and ﬁnally resuspended in PBS, 2%
Triton X and PIC. Protein quantiﬁcation was performed
using the Biorad Protein Assay.
Immunohistochemistry and histological analysis
Immunohistochemistry. For immunoﬂuorescence analysis of
semithin muscle cryosections, animals were anesthetized and
ﬁxed by an intracardiac perfusion of 4% paraformaldehyde,
0.3% glutaraldehyde in PBS. The TA and quadriceps
muscles were then dissected out and post-ﬁxed in the same
ﬁxative for 2 h. After an overnight cryoprotection in 2.3 M
sucrose in PBS containing 0.15 M glycine, biopsies were
frozen in liquid nitrogen. Semithin cryosections of 500 nm
were performed using a FCS cryo-chamber (Leica
Microsystems) mounted on an Ultracut-S ultramicrotome
(Leica Microsystems). Sections were incubated with blocking
buffer (10% FCS in PBS) and stained overnight at 48C
with primary antibodies followed by washing and incubation
with secondary antibodies (alexa 488 goat anti-rabbit IgG
and alexa 594 goat anti-mouse IgG, Molecular Probes). For
immunoﬂuorescence on frozen-muscle, the TA was snap
frozen in liquid nitrogen-cooled isopenthane and sections
(7 mm) were obtained using a cryostat. Sections were ﬁrst
incubated with 5% bovine serum albumin (BSA) in PBS for
1 h at RT and then with r1947 (1:50 and 1:200, for semithin
and frozen sections, respectively) in PBS-5% BSA-0.1%
Brij35 (Sigma) at 378C for 1 h 30 min. After several rinses
in PBS-0.1% Brij35, secondary antibodies (goat anti-rabbit
alexa 488 and goat anti-mouse-CY3, Molecular Probes)
were incutated in PBS for 1 h. Samples were further rinsed
and mounted with FluorSave reagent (Calbiochem) and ana-
lyzed with a confocal microscope (Leica).
Histology. Cross-sections (7 mm) of isopentane-frozen TA
biopsies were stained with hematoxylin and eosin and ana-
lyzed using a Leica microscope coupled with a camera
(Media Cybernetics). The area of muscle ﬁbers and number
of ﬁbers with internal nuclei were measured using Metamorph
software. For NADH-TR reaction, frozen sections were incu-
bated with nitroblue tetrazolium (1 mg/ml, Sigma) and
b-NADH (0 .4 mg/ml, Sigma) in 50 mM Tris–HCl, pH 7.3,
at 578C for 20 min.
Electron microscopy
Immuno-electron microscopy on thawed cryosections. Ultra-
thin cryosections of 70 nm were obtained at 21108Ca s
described above. The immunogold was processed in an
automat (EM IGL, Leica Microsystems) and consisted in:
15 min ﬁxative quenching in 150 mM glycine, rinses in PBS,
30 min blocking in 0.1% BSA and 0.1% cold water ﬁsh skin
gelatine (FSG, Aurion), 1 h incubation in primary antibody
1/100 in PBS containing 0.1% FSG, 1 h incubation
with protein-A coupled with 10 nm colloidal gold particles
(University Medical Center, Utrecht, NL) and postﬁxation in
2.5% glutaraldehyde.
Standard electron microscopy. Muscle biopsies from TA
muscles of anesthetized mice were ﬁxed with 2.5% glutaralde-
hyde in 0.1 M cacodylate buffer (pH 7.2) and processed as
described (12). Semithin sections (2 mm) were stained with
toluidine blue and ultrathin sections (70 nm) were observed
using a Morgagni transmission electron microscope (FEI).
Electron tomography
For electron tomography, semithin sections (200–250 nm)
were cut using an ultracut UC6 (Leica Microsystem), collected
on formvar-carbon coated copper hexagonal 50 mesh grids
and post-stained with 2% Uranyl acetate (W/V) and lead
citrate. Ten nanometer colloidal gold particles were applied
on one side of the grid to be used as ﬁducial markers. Auto-
mated data acquisition of the single tilt series through an
angular range of 2658 to þ658 with 18 increments was per-
formed using an electron microscope equipped with a ﬁeld
emission gun and operating at 200 kV (Tecnai F20, FEI
Company, Eindhoven, The Netherlands) and Xplore 3D.
Tomograms were computed using the SIRT algorithm within
the Inspect3D tomography reconstruction package (FEI).
Three-dimensional surface models were calculated with
AMIRA.
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The isometric contractile properties of EDL and TA muscles
were studied in vitro. Measurements were performed accord-
ing to methods previously detailed (48). Muscles were dis-
sected free from adjacent connective tissue and soaked in an
oxygenated Krebs solution (95% O2 and 5% CO2) containing
(mM): NaCl 118, NaHCO3 25, KCl 5, KH2PO4 1, CaCl2 2.5,
MgSO4 1, glucose 5, maintained at a temperature of 208C.
Muscles were connected at one end to an electromagnetic
puller and at the other end to a force transducer. After equili-
bration (45 min), stimulation (frequency of 125 Hz, train of
stimulation of 300 ms) was delivered through electrodes
running parallel to the muscle. Tetanus isometric contractions
were recorded at L0 (which is determined as the length at
which maximal tetanus isometric force is observed).
Maximal isometric titanic force (P0) was measured. Speciﬁc
P0 (sP0) was calculated by dividing the force by the estimated
cross-section area (CSA) of the muscle. Assuming muscles
have a cylindrical shape and a density of 1.06 mg mm
23,
CSA corresponds to the wet weight of the muscle divided
by its ﬁber length (Lf).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
ACKNOWLEDGEMENTS
We wish to thank Nicolas Guerchet, Josiane Hergueux,
Bernard Gjata and Natasha Darras for help in functional and
histological studies. We are also grateful to Marie Liabeuf
and members of IGBMC mouse house facility for help in
animal care and Erwan Sourty (FEI) for help with the tomo-
graphy software. We are grateful to Jocelyn Laporte for
support and for critical reading of the manuscript. We also
thank Arie Verklej (Utrecht University) for stimulating
discussions.
Conﬂict of Interest statement. None declared.
FUNDING
This study was supported by funds from the Institut National
de la Sante ´ et de la Recherche Me ´dicale, the Centre National
de la Recherche Scientiﬁque, the Ho ˆpital Universitaire de
Strasbourg (HUS), the Colle `ge de France and by grants from
the Association Franc ¸aise contre les Myopathies (AFM), the
National Institutes of Health (P01 NS040828, K08
NS049095), the Muscular Dystrophy Association (USA),
the Joshua Frase and Lee and Penny Anderson Family
Foundations.
REFERENCES
1. Wallgren-Pettersson, C., Clarke, A., Samson, F., Fardeau, M., Dubowitz,
V., Moser, H., Grimm, T., Barohn, R.J. and Barth, P.G. (1995) The
myotubular myopathies: differential diagnosis of the X linked recessive,
autosomal dominant, and autosomal recessive forms and present state of
DNA studies. J. Med. Genet., 32, 673–679.
2. Laporte, J., Biancalana, V., Tanner, S.M., Kress, W., Schneider, V.,
Wallgren-Pettersson, C., Herger, F., Buj-Bello, A., Blondeau, F.,
Liechti-Gallati, S. et al. (2000) MTM1 mutations in X-linked myotubular
myopathy. Hum. Mutat., 15, 393–409.
3. Laporte, J., Hu, L.J., Kretz, C., Mandel, J.L., Kioschis, P., Coy, J.F.,
Klauck, S.M., Poustka, A. and Dahl, N. (1996) A gene mutated in
X-linked myotubular myopathy deﬁnes a new putative tyrosine
phosphatase family conserved in yeast. Nat. Genet., 13, 175–182.
4. Bitoun, M., Maugenre, S., Jaeannet, P., Lacene, E., Ferrer, X., Laforet, P.,
Martin, J., Laporte, J., Lochmuller, H., Beggs, A. et al. (2005) Mutations
in dynamin 2 cause dominant centronuclear myopathy. Nat. Genet., 37,
1207–1209.
5. Bitoun, M., Bevilacqua, J., Prudhon, B., Maugenre, S., Taratuto, A.,
Monges, S., Lubieniecki, F., Cances, C., Uro-Coste, E., Mayer, M. et al.
(2007) Dynamin 2 mutations cause sporadic centronuclear myopathy with
neonatal onset. Ann. Neurol., 62, 666–670.
6. Nicot, A., Toussaint, A., Tosch, V., Kretz, C., Wallgren-Pettersson, C.,
Iwarsson, E., Kingston, H., Garnier, J., Biancalana, V., Oldfors, A. et al.
(2007) Mutations in amphiphysin 2 (BIN1) disrupt its membrane
tubulation properties and its interaction with dynamin 2, and cause
autosomal recessive centronuclear myopathy. Nat. Gene.t, 39,
1134–1139.
7. Herman, G.E., Finegold, M., Zhao, W., de Gouyon, B. and Metzenberg,
A. (1999) Medical complications in long-term survivors with X-linked
myotubular myopathy. J. Pediatr., 134, 206–214.
8. McEntagart, M., Parsons, G., Buj-Bello, A., Biancalana, V., Fenton, I.,
Little, M., Krawczak, M., Thomas, N., Herman, G., Clarke, A. et al.
(2002) Genotype-phenotype correlations in X-linked myotubular
myopathy. Neuromuscul. Disord., 12, 939–946.
9. Mandel, J.-L., Laporte, J., Buj-Bello, A., Sewry, C. and
Wallgren-Pettersson, C. (2002). In Karpati, G. (ed.), Structural and
Molecular basis of skeletal muscle diseases. ISN Neuropath Press, Basel,
pp. 124–129.
10. Pierson, C., Tomczak, K., Agrawal, P., Moghadaszadeh, B. and Beggs, A.
(2005) X-linked myotubular and centronuclear myopathies.
J. Neuropathol. Exp. Neurol., 64, 555–564.
11. Pierson, C., Agrawal, P., Blasko, J. and Beggs, A. (2007) Myoﬁber size
correlates with MTM1 mutation type and outcome in X-linked
myotubular myopathy. Neuromuscul. Disord., 17, 562–568.
12. Buj-Bello, A., Laugel, V., Messaddeq, N., Laporte, J., Pellissier, J.-F. and
Mandel, L. (2002) The lipid phosphatase myotubularin is esential for
skeletal muscle maintenance but not myogenesis in mice. Proc. Natl
Acad. Sci. USA, 11, 2297–2307.
13. Bolino, A., Muglia, M., Conforti, F.L., LeGuern, E., Salih, M.A.,
Georgiou, D.M., Christodoulou, K., Hausmanowa-Petrusewicz, I.,
Mandich, P., Schenone, A. et al. (2000) Charcot-Marie-Tooth type 4B is
caused by mutations in the gene encoding myotubularin-related protein-2.
Nat. Genet., 25, 17–19.
14. Azzedine, H., Bolino, A., Taieb, T., Birouk, N., Di Duca, M., Bouhouche,
A., Benamou, S., Mrabet, A., Hammadouche, T., Chkili, T. et al. (2003)
Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2
and Sbf1, in two families with an autosomal recessive demyelinating form
of Charcot-Marie-Tooth disease associated with early-glaucoma.
Am. J. Hum. Gene.t, 72, 1141–1153.
15. Senderek, J., Bergmann, C., Weber, S., Ketelsen, U., Schorle, H.,
Rudnik-Schoneborn, S., Buttner, R., Buchheim, E. and Zerres, K. (2003)
Mutation of the SBF2 gene, encoding a novel member of the myotubularin
family, in Charcot-Marie-Tooth neuropathy type 4B2/11p15. Hum. Mol.
Genet., 12, 349–356.
16. Laporte, J., Bedez, F., Bolino, A. and Mandel, J. (2003) Myotubularins, a
large disease-associated family of cooperating catalytically active and
inactive phosphoinositides phosphatases. Hum. Mol. Genet., 12 (Spec no.
2), R285–R292.
17. Robinson, F. and Dixon, J. (2006) Myotubularin phosphatases: policing
3-phosphoinositides. Trends Cell Biol., 16, 403–412.
18. Blondeau, F., Laporte, J., Bodin, S., Superti-Furga, G., Payrastre, B. and
Mandel, J.L. (2000) Myotubularin, a phosphatase deﬁcient in myotubular
myopathy, acts on phosphatidylinositol 3-kinase and phosphatidylinositol
3-phosphate pathway. Hum. Mol. Genet., 9, 2223–2229.
19. Zhao, R., Qi, Y., Chen, J. and Zhao, Z.J. (2001) FYVE-DSP2, a FYVE
domain-containing dual speciﬁcity protein phosphatase that
dephosphorylates phosphatidylinositol 3-phosphate. Exp. Cell Res., 265,
329–338.
2142 Human Molecular Genetics, 2008, Vol. 17, No. 1420. Laporte, J., Blondeau, F., Gansmuller, A., Lutz, Y., Vonesch, J.-L. and
Mandel, L. (2002) The PtdIns3P phosphatase myotubularin is a
cytoplasmic protein that also localizes to Rac1-inducible plasma
membrane rufﬂes. J. Cell Sci., 115, 3105–3117.
21. Mochizuki, Y. and Majerus, P. (2003) Characterization of
myotubularin-related protein 7 and its binding partner,
myotubularin-related protein 9. Proc. Natl Acad. Sci. USA, 100,
9768–9773.
22. Lorenzo, O., Unrbe ´, S. and Clague, M. (2005) Systematic analysis of
myotubularins: heterodimeric interactions, subcellular localization and
endosome-related functions. J. Cell Sci., 119, 2953–2959.
23. Cao, C., Laporte, J., Backer, J., Wandinger-Ness, A. and Stein, M. (2007)
Myotubularin lipid phosphatase binds the hVPS15/hVPS34 lipid kinase
complex on endosomes. Trafﬁc, 8, 1052–1067.
24. Tsujita, K., Itoh, T., Ijuin, T., Yamamoto, A., Shisheva, A., Laporte, J. and
Takenawa, T. (2004) Myotubularin regulates the function of the late
endosome through the GRAM domain-phosphatidylinositol
3,5-biphosphate interaction. J. Biol. Chem., 279, 13817–13824.
25. Wu, Z., Asokan, A. and Samulski, R. (2006) Adeno-associated virus
serotypes: vector toolkit for human gene therapy. Mol. Ther., 14,
316–327.
26. Engel, A. and Banker, A. (2004) Ultrastructural changes in diseased
muscle. In Engel, A. and Franzini-Armstrong, C. (eds), Myology.
McGraw-Hill, pp. 762–766.
27. Goyenvalle, A., Vulin, A., Fougerousse, F., Leturcq, F., Kaplan, J.,
Garcia, L. and Danos, O. (2004) Rescue of dystrophic muscle through U7
snRNA-mediated exon skipping. Science, 306, 1796–1799.
28. Blankinship, M., Gregorevic, P. and Chamberlain, J. (2006) Gene therapy
strategies for Duchenne muscular dystrophy utilizing recombinant
adeno-associated virus vectors. Mol. Ther., 13, 241–249.
29. Qiao, C., Li, J., Zhu, T., Draviam, R., Watkins, S., Ye, X., Chen, C., Li, J.
and Xiao, X. (2005) Amelioration of laminin-alpha-2-deﬁcient congenital
muscular dystrophy by somatic gene transfer of miniagrin. Proc. Natl
Acad. Sci. USA, 102, 11999–12004.
30. Fougerousse, F., Bartoli, M., Poupiot, J., Arandel, L., Durand, M.,
Guerchet, N., Gicquel, E., Danos, O. and Richard, I. (2007) Phenotypic
correction of a-sarcoglycan deﬁciency by intra-arterial injection of a
muscle-speciﬁc serotype 1 rAAV vector. Mol. Ther., 15, 53–61.
31. Wang, Z., Kuhr, C., Allen, J., Blankinship, M., Gregorevic, P.,
Chamberlain, J., Tapscott, S. and Storb, R. (2007) Sustained
AAV-mediated dystrophin expression in a canine model of Duchenne
muscular dystrophy with a brief course of immunosuppression. Mol.
Ther., 15, 1160–1166.
32. Wang, Z., Zhu, T., Qiao, C., Zhou, L., Wang, B., Zhang, J., Chen, C., Li,
J. and Xiao, X. (2005) Adeno-associated virus serotype 8 efﬁciently
delivers genes to muscle and heart. Nat. Biotechnol., 23, 321–328.
33. Denti, M., Rosa, A., D’Antona, G., Sthandier, O., De Angelis, F.,
Nicoletti, C., Allocca, M., Pansarasa, O., Parente, V., Musaro `, A. et al.
(2006) Body-wide gene therapy of Duchenne muscular dystrophy in the
mdx mouse model. Proc. Natl Acad. Sci. USA, 103, 3758–3763.
34. Karpati, G., Hilton-Jones, D. and Griggs, R. (2001)Disorders of Voluntary
Muscle. Cambridge University Press.
35. Dorchies, O.M., Laporte, J., Wagner, S., Hindelang, C., Warter, J.,
Mandel, J. and Poindron, P. (2001) Normal innervation and differentiation
of X-linked myotubular myopathy muscle cells in a nerve-muscle
coculture system. Neuromuscul. Disord., 11, 736–746.
36. Parton, R., Way, M., Zorzi, N. and Stang, E. (1997) Caveolin-3 associates
with developing T-tubules during muscle differentiation. J. Cell Biol.,
136, 137–154.
37. Galbiati, F., Engelman, J., Volonte, D., Zhang, X., Minetti, C., Li, M.,
Hou, H.J., Kneitz, B., Edelmann, W. and Lisanti, M. (2001) Caveolin-3
null mice show a loss of caveolae, changes in the microdomain
distribution of the dystrophin-glycoprotein complex, and t-tubule
abnormalities. J. Biol. Chem., 276, 21425–21433.
38. Sarnat, H.B. (1990) Myotubular myopathy: arrest of morphogenesis of
myoﬁbers associated with persistence of fetal vimentin and desmin. Four
cases compared with fetal and neonatal muscle. Can. J. Neurol. Sci., 17,
109–123.
39. Zhang, P., Chen, X. and Fan, M. (2007) Signaling mechanisms involved
in disuse muscle atrophy. Med. Hypotheses, 69, 310–321.
40. Razzaq, A., Robinson, I., McMahon, H., Skepper, J., Su, Y., Zelhof, A.,
Jackson, A., Gay, N. and O’Kane, C. (2001) Amphiphysin is necessary for
organization of the excitation–contraction coupling machinery of
muscles, but not for synaptic vesicle endocytosis in Drosophila. Genes
Dev., 15, 2967–2979.
41. Lee, E., Marcucci, M., Daniell, L., Pypaert, M., Weisz, O., Ochoa, G.,
Farsad, K., Wenk, M. and De Camilli, P. (2002) Amphiphysin 2 (Bin1)
and T-tubule biogenesis in muscle. Science, 297, 1193–1196.
42. Inose, M., Higuchi, I., Nakagawa, M., Kashio, N. and Osame, M. (1999)
Caveolin-3 and sarcoglycans in the vacuolar myopathies and
centronuclear myopathy. Muscle Nerve, 22, 1080–1086.
43. Zuchner, S., Noureddine, M., Kennerson, M., Verhoeven, K., Claeys, K.,
De Jonghe, P., Merory, J., Oliveira, S., Speer, M., Stenger, J. et al. (2005)
Mutations in the pleckstrin homology domain of dynamin 2 cause
dominant intermediate Charcot-Marie-Tooth disease. Nat. Genet., 37,
289–294.
44. Fabrizi, G., Ferrarini, M., Cavallaro, T., Cabrini, I., Cerini, R., Bertolasi,
L. and Rizzuto, N. (2007) Two novel mutations in dynamin-2 cause
axonal Charcot-Marie-Tooth disease. Neurology, 69, 291–295.
45. Musaro, A., McCullagh, K., Paul, A., Houghton, L., Dobrowolny, G.,
Molinaro, M., Barton, E., Sweeney, H. and Rosenthal, N. (2001)
Localized Igf-1 transgene expression sustains hypertrophy and
regeneration in senescent skeletal muscle. Nat. Genet., 27, 195–200.
46. Chaussade, C., Pirola, L., Bonnafous, S., Blondeau, F., Brenz-Verca, S.,
Tronche `re, H., Portis, F., Rusconi, S., Payrastre, B., Laporte, J. et al.
(2003) Expression of myotubularin by an adenoviral vector demonstrates
its function as a phosphatidylinositol 3-phosphate [PtdIns(3)P]
phosphatase in muscle cell lines: involvement of PtdIns(3)P in
insulin-stimulated glucose transport. Mol. Endocrinol., 17, 2448–2460.
47. Xiao, X., Li, J. and Samulski, R. (1998) Production of high-titer
recombinant adeno-associated virus vectors in the absence of helper
adenovirus. J. Virol., 72, 2224–2232.
48. Fougerousse, F., Gonin, P., Durand, M., Richard, I. and Raymackers, J.
(2003) Force impairment in calpain 3-deﬁcient mice is not correlated with
mechanical disruption. Muscle Nerve, 27, 616–623.
Human Molecular Genetics, 2008, Vol. 17, No. 14 2143